ROCHESTER, N.Y., Nov. 30 /PRNewswire/ -- Vaccinex, Inc. announced today the award of a key European patent (European Patent No. 1340088) for its antibody discovery technology platform, branded as ActivMab(R) Technology. Vaccinex is using its patented technology to discover and develop new monoclonal antibody therapies, and has advanced four of its lead therapeutic antibodies into pre-clinical drug development.
"This European patent, and related patents already awarded in the United States and elsewhere, underscores the novelty of our discovery technology, which gives Vaccinex important advantages over competitors in the area of therapeutic antibodies," said Dr. Maurice Zauderer, President & CEO. "Vaccinex is leveraging this patented technology in partnerships with established leaders in the antibody market as we continue to build a pipeline of promising antibody therapies."
The market for antibody therapies is estimated at $25 billion in 2007, and is projected to reach $43 billion by 2012. For additional information about Vaccinex, please visit the company's website at www.vaccinex.com.
CONTACT: Raymond Watkins, VP of Operations and Officer, +1-585-271-2700
Web site: http://www.vaccinex.com//